decisionhealth Newsletters, Part B News - 2008 Issue 7 (July)
Nerve conduction device shows risks and rewards of buying new diagnostic equipment
Subscribe or sign in to view the full article.
Article Overview
This article examines how a new nerve conduction testing device changed who performs nerve conduction studies and how those services are billed. It covers the clinical debate between specialty groups, the reimbursement and coding uncertainty, and the broader business risks for a medical device company and its users. The piece is relevant to physicians, billing staff, compliance teams, and anyone following Medicare and AMA coding policy for neurodiagnostic testing.
Why This Topic Matters
The article highlights how changes in technology can disrupt established specialty workflows, create payer disputes, and leave providers uncertain about how to report and reimburse diagnostic services.
Article Sections
-
Technology adoption and specialty shift
Introduces the device and explains how it expanded access to nerve conduction testing beyond traditional specialty settings. Describes the change in utilization patterns and the resulting interest from primary care practices.
-
Clinical effectiveness and professional disagreement
Summarizes the dispute between specialty groups over the device’s performance and the interpretation of test results. Covers differing views on training, completeness of testing, and the role of related neurodiagnostic work.
-
The question of reimbursement
Reviews the coding and payment uncertainty affecting nerve conduction testing under the new device. Mentions AMA and CMS involvement, local coverage variation, and the uncertainty facing the manufacturer.
-
The future of NC-Stat
Discusses the financial and market impact on the device manufacturer and notes the company’s next-generation product strategy. Emphasizes the continuing uncertainty around adoption and payment policy.
What You Will Learn
- How a new diagnostic device can change the clinical setting in which nerve conduction studies are performed.
- Why specialty groups may disagree about the clinical adequacy of a diagnostic technology.
- How reimbursement uncertainty can affect coding policy, provider adoption, and manufacturer risk.
- What kinds of Medicare and AMA policy issues can arise when a new device is introduced into established billing workflows.
Who Should Read This
- Medical coders
- Billing and reimbursement staff
- Compliance professionals
- Physicians
- Practice managers
- Health policy analysts
- Medical device stakeholders
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com